- Open Access
Possible mechanism and clinical potentials of allostery
© Huang and López Villar; licensee Springer. 2014
- Received: 20 February 2014
- Accepted: 16 June 2014
- Published: 3 July 2014
Allostery is involved in the dynamic regulation of biological functions in proteins. Advances in allostery research have recently drawn great interest and brought allostery closer to the clinic. The present commentary describes the mechanism by which allostery may involve in from a cell-wide view and its contribution to the discovery of new therapeutics to diseases.
Allostery is a universal phenomenon whereby an effector molecule combining with a (allosteric) site on the protein surface leads to a functional change through alteration of shape and/or dynamics, to regulate protein activity. Effector perturbations can result from a wide range of biological and physical phenomena, including the binding of a small effector molecule, post-translational modifications, protein binding, temperature changes, and pH changes. Allostery takes place in all dynamic proteins, single chains, and in RNA and DNA polymers.
Numerous studies demonstrated the importance of the allostery on the protein level, such as MAP kinase, G-protein-coupled receptor (GRCR) kinase, glucokinase (GCK), Hemoglobin S etc. to involve in gene regulation [1–4]. Evolution has exploited allostery as a crucial protein property and optimized it for function [5, 6]. Recently, a series of studies reported that the allostery also occurred through RNA and DNA, in addition to the protein level. Three DNA-protein pairs (Cy3B-labled DNA binding domain of glucocorticoid receptor (GRDBD) together with BamHI, Lac repressor (LacR) with EcoRV, or LacR with T7 RNA polymerase) were used to validate and quantitatively characterize the allostery [7–9]. The deformation of the double-helical structure was suggested to be the origin of DNA allostery. However, the altered distance of half a helical turn might affect the evolution with fine-tuning capability of adjusting relative kinetics in regulatory networks. Allostery through DNA was found to be more relative to the placement of regulatory elements such as the transmission of structural influences and switches between canonical structural models.
However, people gradually found that the fundamental importance of allostery is not in the protein or DNA level but, rather, on the cells. From a cell-wide view, allosteric changes can function through a number of pathways which are communicated within, across and between cells. Allostery propagates via molecular cooperativeness and recognition specificity, and affects consecutive components in cellular pathways. The main standpoints to descript how allostery works are thermodynamics, free energy landscape of population shift, and structure [10, 11]. Allosteric proteins could activate the conformation of different kinase families and may share a similar structure and the same mechanism. Upstream allosteric sites could switch from inactive αC-helix-out state (OFF) to the active αC-helix-in conformation (ON) . It promotes the inter-connection with several signaling pathways and the formation of allostery network linkage. When mutations cause a high population of ON or OFF states, or lead to an irreversible change in active site shape and dynamics, the allosteric diseases occur . Based on such principle, allosteric drugs targeted at those structures and pathways will provide the possibility of new therapeutics. These pathways may include PI3K/Akt1, MEK1, PDK1 and other protein kinases family pathways . For example, a new model for allosteric regulation of phenylalanine hydroxylase has been studied and ACT interface may be the potential molecule target for therapy . Allosteric ligands bind to protein receptors such as GPCRs also provide the ways for allosteric drugs screening and leading to potential therapeutic benefit .
The work was supported by Shanghai Health Bureau Research Fund (No. 2010/50), The National Nature Science Foundation of China (91230204, 81270099, 81320108001, 81270131), The Shanghai Committee of Science and Technology (12JC1402200, 12431900207, 11410708600), and Spanish health system “Dr E. Lopez Villar, BOE 2012”, ISCIII (PI13/02475FIS “BOE 2013”).
- Coyle SM, Flores J, Lim WA: Exploitation of latent allostery enables the evolution of new modes of MAP Kinase regulation. Cell 2013, 154(4):875–887. 10.1016/j.cell.2013.07.019PubMed CentralView ArticlePubMedGoogle Scholar
- Larion M, Salinas RK, Bruschweiler Li L, Miller BG, Bruschweiler R: Order–disorder transitions govern kinetic cooperativity and allostery of monomeric human glucokinase. PLoS Biol 2012, 10(12):1001452. 2012–01–20 2012-01-20 10.1371/journal.pbio.1001452View ArticleGoogle Scholar
- Liggett SB: Phosphorylation barcoding as a mechanism of directing GPCR signaling. Sci Signal 2011, 4(185):e36. 2011–08–09 2011-08-09View ArticleGoogle Scholar
- Weinkam P, Sali A: Mapping polymerization and allostery of hemoglobin s using point mutations. J Phys Chem B 2013, 117(42):13058–68. 2013–09–09 2013-09-09 10.1021/jp4025156PubMed CentralView ArticlePubMedGoogle Scholar
- Harms MJ, Thornton JW: Evolutionary biochemistry: revealing the historical and physical causes of protein properties. Nat Rev Genet 2013, 14(8):559–571. 2013–08–01 2013-08-01 10.1038/nrg3540PubMed CentralView ArticlePubMedGoogle Scholar
- De Juan D, Pazos F, Valencia A: Emerging methods in protein co-evolution. Nat Rev Genet 2013, 14(4):249–261. 2013–04–01 2013-04-01View ArticlePubMedGoogle Scholar
- Kim S, Brostromer E, Xing D, Jin J, Chong S, Ge H, Wang S, Gu C, Yang L, Gao YQ, Su XD, Sun Y, Xie XS: Probing allostery through DNA. Science 2013, 339(6121):816–819. 2013–02–15 2013-02-15 10.1126/science.1229223PubMed CentralView ArticlePubMedGoogle Scholar
- Chen I: Allostery through DNA. Nat Struct Mol Biol 2013, 20(4):410. 2013–04–01 2013-04-01 10.1038/nsmb0413-410View ArticlePubMedGoogle Scholar
- Crothers DM: Biophysics. Fine tuning gene regulation. Science 2013, 339(6121):766–767. 2013–02–15 2013-02-15 10.1126/science.1232663View ArticlePubMedGoogle Scholar
- Tsai C, Nussinov R: A unified view of “How Allostery Works”. PLoS Comput Biol 2014, 10(2):e1003394. 2014–02–06 2014-02-06 10.1371/journal.pcbi.1003394PubMed CentralView ArticlePubMedGoogle Scholar
- Motlagh HN, Wrabl JO, Li J, Hilser VJ: The ensemble nature of allostery. Nature 2014, 508(7496):331–339. 2014–04–16 2014-04-16 10.1038/nature13001PubMed CentralView ArticlePubMedGoogle Scholar
- Huse M, Kuriyan J: The conformational plasticity of protein kinases. Cell 2002, 109(3):275–282. 2002–05–03 2002-05-03 10.1016/S0092-8674(02)00741-9View ArticlePubMedGoogle Scholar
- Nussinov R, Tsai CJ: Allostery in disease and in drug discovery. Cell 2013, 153(2):293–305. 2013–04–11 2013-04-11 10.1016/j.cell.2013.03.034View ArticlePubMedGoogle Scholar
- Lu S, Li S, Zhang J: Harnessing allostery: a novel approach to drug discovery. Med Res Rev 2014. doi:10.1002/med.21317.[Epub ahead of print]. doi:10.1002/med.21317.[Epub ahead of print].Google Scholar
- Jaffe EK, Stith L, Lawrence SH, Andrake M, Dunbrack RJ: A new model for allosteric regulation of phenylalanine hydroxylase: implications for disease and therapeutics. Arch Biochem Biophys 2013, 530(2):73–82. 2013–02–15 2013-02-15 10.1016/j.abb.2012.12.017PubMed CentralView ArticlePubMedGoogle Scholar
- Wootten D, Christopoulos A, Sexton PM: Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 2013, 12(8):630–644. 2013–08–02 2013-08-02 10.1038/nrd4052View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.